Austin J. Kosier, M.D.; Decision and Order, 4941-4943 [2022-01834]
Download as PDF
4941
Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices
denial. Careless or negligent handling of
controlled substances creates the
opportunity for diversion and [can]
justify the revocation of an existing
registration . . .’’ Bobby D. Reynolds,
N.P., Tina L. Killebrew, N.P., & David R.
Stout, N.P., 80 FR 28643, 28662 (2015)
(quoting Paul J. Caragine, Jr. 63 FR
51592, 51601 (1998). In fact, the Agency
has found in favor of revocation in cases
where registrants have failed to
document their prescribing decisions—
a violation which has been clearly
established in this case. The Agency has
repeatedly emphasized that
‘‘[c]onscientious documentation is . . .
not just a ministerial act, but a key
treatment tool and vital indicator to
evaluate whether the physician’s
prescribing practices are within the
usual course of professional practice.’’
Cynthia M. Cadet, M.D., 76 FR 19,450,
19,464 (2011) (internal citation and
quotation omitted); see also Kaniz F.
Khan-Jaffery, M.D., 85 FR 45,667, 45,686
(2020) (‘‘DEA’s ability to assess whether
controlled substances registrations are
consistent with the public interest is
predicated upon the ability to consider
the evidence and rationale of the
practitioner at the time that she
prescribed a controlled substance—
adequate documentation is critical to
that assessment.’’).
The case at hand demonstrates
prescribing beneath the applicable
standard of care and outside the usual
course of professional practice in
California to multiple patients over the
course of many years. I agree with the
Chief ALJ that this conduct was
egregious and I agree with his rationale
for sanction. As stated above, for many
reasons, I cannot find that I can entrust
Respondent with a registration.
Accordingly, I reject Respondent’s
Exceptions and affirm the RD’s
conclusion that Respondent’s
registration should be revoked.
in California. This Order is effective
March 2, 2022.
Anne Milgram,
Administrator.
[FR Doc. 2022–01838 Filed 1–28–22; 8:45 am]
khammond on DSKJM1Z7X2PROD with NOTICES
VerDate Sep<11>2014
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–947]
Bulk Manufacturer of Controlled
Substances Application: Siegfried
USA, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Jkt 256001
9333
9630
9652
9780
Schedule
II
II
II
II
The company plans to manufacture
the above-listed controlled substance in
bulk for development of a new active
pharmaceutical ingredient (API) and
validation for a Drug Master File
submission to the Food and Drug
Administration. No other activity for
this drug code is authorized for this
registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2022–01816 Filed 1–28–22; 8:45 am]
BILLING CODE P
Siegfried USA, LLC. has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplementary Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 1, 2022 Such persons
may also file a written request for a
hearing on the application on or before
April 1, 2022.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUMMARY:
In
accordance with 21 CFR 1301.33(a), this
is notice that on December 8, 2021,
Siegfried USA, LLC., 33 Industrial Park
Road, Pennsville, New Jersey 08070–
3244, applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Drug
code
Controlled substance
17:38 Jan 28, 2022
Thebaine .................................
Opium tincture ........................
Oxymorphone .........................
Tapentadol ..............................
Drug
code
BILLING CODE 4410–09–P
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a)(4) and 21 U.S.C. 823(f), I hereby
revoke DEA Certificate of Registration
No. BC1317165 issued to Bradley H.
Chesler, M.D. Pursuant to 28 CFR
0.100(b) and the authority vested in me
by 21 U.S.C. 824(a) and 21 U.S.C. 823(f),
I further hereby deny any pending
application of Bradley H. Chesler, M.D.,
to renew or modify this registration, as
well as any other pending application of
Bradley H. Chesler, M.D. for registration
Controlled substance
Gamma Hydroxybutyric Acid ..
Dihydromorphine .....................
Hydromorphinol .......................
Amphetamine ..........................
Lisdexamfetamine ...................
Methylphenidate ......................
Amobarbital .............................
Pentobarbital ...........................
Secobarbital ............................
Phenylacetone ........................
Codeine ...................................
Oxycodone ..............................
Hydromorphone ......................
Hydrocodone ...........................
Methadone ..............................
Methadone intermediate .........
Morphine .................................
Oripavine .................................
PO 00000
Frm 00110
Fmt 4703
Schedule
2010
9145
9301
1100
1205
1724
2125
2270
2315
8501
9050
9143
9150
9193
9250
9254
9300
9330
Sfmt 4703
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 22–4]
Austin J. Kosier, M.D.; Decision and
Order
On September 30, 2021, the Acting
Assistant Administrator, Diversion
Control Division, Drug Enforcement
Administration (hereinafter, DEA or
Government), issued an Order to Show
Cause (hereinafter, OSC) to Austin J.
Kosier, M.D. (hereinafter, Respondent)
of Zanesville, Ohio. OSC, at 1 and 3.
The OSC proposed the revocation of
Respondent’s Certificate of Registration
No. FK6714504. It alleged that
Respondent ‘‘[does] not have authority
to dispense or prescribe controlled
substances in the [s]tate of Ohio, the
state in which [Respondent is]
registered with DEA.’’ Id. at 1 (citing 21
U.S.C. 824(a)(3)).
Specifically, the OSC alleged that on
or about May 12, 2021, the State
Medical Board of Ohio issued an Order
suspending Respondent’s state license
to practice medicine and surgery. Id. at
2. The Order was effective immediately
and ordered that Respondent
‘‘immediately cease the practice of
medicine and surgery in Ohio.’’ Id.
The OSC notified Respondent of the
right to request a hearing on the
allegations or to submit a written
statement, while waiving the right to a
hearing, the procedures for electing each
option, and the consequences for failing
to elect either option. Id. at 2 (citing 21
CFR 1301.43). The OSC also notified
Respondent of the opportunity to
submit a corrective action plan. Id. at 3
(citing 21 U.S.C. 824(c)(2)(C)).
E:\FR\FM\31JAN1.SGM
31JAN1
4942
Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
On October 25, 2021, Respondent
timely requested a hearing by email.1
Administrative Law Judge Exhibit
(hereinafter, ALJX) 4 (Request for
Hearing). Respondent’s Request for
Hearing also indicated that Respondent
was ‘‘considering the submission of a
corrective action plan.’’ Id.
The Office of Administrative Law
Judges put the matter on the docket and
assigned it to Administrative Law Judge
Teresa A. Wallbaum (hereinafter, the
ALJ). On October 25, 2021, the ALJ
issued a Briefing Schedule. See ALJX 5.
The Government timely complied with
the Briefing Schedule by filing a Notice
of Filing of Evidence and Motion for
Summary Disposition (hereinafter,
Motion for Summary Disposition) on
November 10, 2021. Order Granting the
Government’s Motion for Summary
Disposition, and Recommended
Rulings, Findings of Fact, Conclusions
of Law, and Decision of the
Administrative Law Judge (hereinafter,
Recommended Decision or RD), at 2; see
also ALJX 6. In its Motion for Summary
Disposition, the Government requested
summary disposition and recommended
that Respondent’s DEA registration be
revoked based on Respondent’s lack of
authority to handle controlled
substances in Ohio, the state in which
he is registered with the DEA. Motion
for Summary Disposition, at 5. On
November 30, 2021, Respondent
untimely filed a Memorandum in
Opposition of Respondent [sic] to
Government’s Motion for Summary
Disposition (hereinafter, Respondent’s
Opposition). RD, at 2; see also ALJX 7.2
Respondent’s Opposition argued that
there ‘‘does not exist and [sic] mandate
under the [Controlled Substances Act]
whereas [the] tribunal shall or must
revoke or suspend the [DEA registration]
of a physician under a state summary
suspension.’’ Respondent’s Opposition,
at 1. Respondent’s Opposition also
noted that Respondent’s state medical
license, though suspended, was still
1 Though the Request for Hearing itself is
undated, the record indicates that the Request for
Hearing was filed on October 25, 2021. See Order
Directing the Government to File Evidence
Regarding its Lack of State Authority Allegation and
Briefing Schedule (hereinafter, Briefing Schedule),
at 1. I find that the Government’s service of the OSC
was adequate and that the Request for Hearing was
timely filed on October 25, 2021.
2 As a result of Respondent’s untimely filing, on
November 30, 2021, the ALJ issued an Order to
Show Good Cause Regarding Respondent’s Late
Filing (hereinafter, Order to Show Good Cause). See
ALJX 8. On November 30, 2021, Respondent timely
filed a Response to Order to Show Good Cause
stating that the untimely filing was due to a death
in Respondent’s counsel’s family. RD, at 2; see also
ALJX 9. The ALJ found that ‘‘the delay was minimal
and caused no prejudice to the Government’’ and
thus accepted Respondent’s Opposition. RD, at 2.
VerDate Sep<11>2014
17:38 Jan 28, 2022
Jkt 256001
intact; 3 that ‘‘[t]he issue that led to his
current case [was] unrelated to the
practice of medicine and was in no way
arose [sic] in the course and scope of
practice’’; 4 and that ‘‘[Respondent] has
had no previous issues in any way with
his medical license in the past.’’ Id.
Moreover, Respondent’s Opposition
highlighted ‘‘the unbelievable work
[Respondent] has done and is
continuing to do within the medical
community and specifically an online
training and tutorial platform for health
care practitioners and medical students
around the world.’’ Id. at 2–3. Finally,
Respondent’s Opposition highlighted
that Respondent ‘‘has also taken [the]
opportunity to maintain and enhance
his own medical education’’ with CME
courses. Id. at 3. Respondent’s
Opposition sought the denial of the
Government’s Motion for Summary
Disposition and for the Tribunal to
either grant Respondent’s request for a
hearing or to stay the matter pending the
outcome of the Ohio Medical Board
hearing. Id.
On December 2, 2021, the ALJ granted
the Government’s Motion for Summary
Disposition, finding that ‘‘[t]here is no
genuine issue of material fact in this
case’’ because ‘‘[t]he Government has
established that Respondent currently
lacks a medical license.’’ RD, at 7–8.
The ALJ recommended that
Respondent’s DEA registration be
revoked and that any application to
renew or modify his DEA registration be
denied ‘‘because Respondent lacks state
authority to handle controlled
substances in Ohio.’’ Id. at 8. By letter
dated December 27, 2021, the ALJ
certified and transmitted the record to
me for final Agency action. Transmittal
Letter, at 1. The ALJ also advised that
neither party filed exceptions. Id.
I issue this Decision and Order based
on the entire record before me. 21 CFR
1301.43(e). I make the following
findings of fact.
Findings of Fact
Respondent’s DEA Registration
According to Agency records,
Respondent is the holder of DEA
Certificate of Registration No.
FK6714504 at the registered address of
3 According
to Respondent’s Opposition, the Ohio
Medical Board ‘‘issued a summary suspension
pending the outcome of a Medical Board Hearing
in January of 2022.’’ Id. at 2. Further, according to
Respondent’s Opposition, the suspension ‘‘was
based on a provision in the Ohio Administrative
Code that allows the Ohio Medical Board to
summarily suspend a license of a physician based
on [the] physician’s entry into an intervention
program to address a mental health matter’’ and
‘‘[t]he matter at hand with [Respondent] is his
ongoing struggle with his homosexuality.’’ Id.
4 See supra n.3.
PO 00000
Frm 00111
Fmt 4703
Sfmt 4703
2916 Vangader Dr., Zanesville, OH
43701. Pursuant to this registration,
Respondent is authorized to dispense
controlled substances in Schedules II
through V as a practitioner.
Respondent’s registration expires on
December 31, 2022.
The Status of Respondent’s State
License
On May 12, 2021, the State Medical
Board of Ohio (hereinafter, the Board)
issued a Notice of Summary Suspension
and Opportunity for Hearing
(hereinafter, Summary Suspension) and
an Entry of Order. Government Exhibit
(hereinafter, GX) A, at 3 and 5.
According to the Summary Suspension,
on or about December 16, 2019, ‘‘the
Franklin County Court of Common Pleas
filed an indictment alleging
[Respondent] had committed attempted
unlawful sexual contact with a minor’’
on or about September 10, 2019. Id.
Further, according to the Summary
Suspension, ‘‘[o]n or about November
13, 2020, [Respondent] appeared before
the Court for a hearing on [his]
application for intervention in lieu of
conviction for these offenses’’ and ‘‘[t]he
Court granted [Respondent’s]
application.’’ Id. The Summary
Suspension states that ‘‘[Respondent]
pleaded guilty to [the] felony offenses at
a subsequent hearing held on or about
December 9, 2020’’ and ‘‘[t]he Court
ordered further proceedings be stayed
while [Respondent was] under
community control.’’ Id. In its Entry of
Order on May 12, 2021, the Board found
that ‘‘[Respondent’s] continued practice
presents a danger of immediate and
serious harm to the public’’ and
ordered, effective immediately, that
Respondent’s license to practice
medicine and surgery in the state of
Ohio be summarily suspended, that
Respondent ‘‘immediately cease the
practice of medicine and surgery in
Ohio,’’ and that Respondent
‘‘immediately refer all active patients to
other appropriate physicians.’’ Id. at 3.
According to Ohio’s online records, of
which I take official notice,
Respondent’s medical license is still
suspended and inactive.5 Ohio License
5 Under the Administrative Procedure Act, an
agency ‘‘may take official notice of facts at any stage
in a proceeding—even in the final decision.’’
United States Department of Justice, Attorney
General’s Manual on the Administrative Procedure
Act 80 (1947) (Wm. W. Gaunt & Sons, Inc., Reprint
1979). Pursuant to 5 U.S.C. 556(e), ‘‘[w]hen an
agency decision rests on official notice of a material
fact not appearing in the evidence in the record, a
party is entitled, on timely request, to an
opportunity to show the contrary.’’ Accordingly,
Respondent may dispute my finding by filing a
properly supported motion for reconsideration of
findings of fact within fifteen calendar days of the
E:\FR\FM\31JAN1.SGM
31JAN1
Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
Look Up, https://elicense.ohio.gov/oh_
verifylicense (last visited date of
signature of this Order). Accordingly, I
find that Respondent is not currently
licensed to practice medicine in Ohio,
the state in which he is registered with
the DEA.
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the
Attorney General is authorized to
suspend or revoke a registration issued
under section 823 of the Controlled
Substances Act (hereinafter, CSA)
‘‘upon a finding that the registrant . . .
has had his State license or registration
suspended . . . [or] revoked . . . by
competent State authority and is no
longer authorized by State law to engage
in the . . . dispensing of controlled
substances.’’ With respect to a
practitioner, the DEA has also long held
that the possession of authority to
dispense controlled substances under
the laws of the state in which a
practitioner engages in professional
practice is a fundamental condition for
obtaining and maintaining a
practitioner’s registration. See, e.g.,
James L. Hooper, M.D., 76 FR 71,371
(2011), pet. for rev. denied, 481 F. App’x
826 (4th Cir. 2012); Frederick Marsh
Blanton, M.D., 43 FR 27616, 27617
(1978).
This rule derives from the text of two
provisions of the CSA. First, Congress
defined the term ‘‘practitioner’’ to mean
‘‘a physician . . . or other person
licensed, registered, or otherwise
permitted, by . . . the jurisdiction in
which he practices . . . , to distribute,
dispense, . . . [or] administer . . . a
controlled substance in the course of
professional practice.’’ 21 U.S.C.
802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a practitioner
possess state authority in order to be
deemed a practitioner under the CSA,
the DEA has held repeatedly that
revocation of a practitioner’s registration
is the appropriate sanction whenever he
is no longer authorized to dispense
controlled substances under the laws of
the state in which he practices. See, e.g.,
James L. Hooper, 76 FR 71371–72;
Sheran Arden Yeates, M.D., 71 FR
date of this Order. Any such motion and response
shall be filed and served by email to the other party
and to Office of the Administrator, Drug
Enforcement Administration at
dea.addo.attorneys@dea.usdoj.gov.
VerDate Sep<11>2014
17:38 Jan 28, 2022
Jkt 256001
39130, 39131 (2006); Dominick A. Ricci,
M.D., 58 FR 51104, 51105 (1993); Bobby
Watts, M.D., 53 FR 11919, 11920 (1988);
Frederick Marsh Blanton, 43 FR 27617.
Moreover, because ‘‘the controlling
question’’ in a proceeding brought
under 21 U.S.C. 824(a)(3) is whether the
holder of a practitioner’s registration ‘‘is
currently authorized to handle
controlled substances in the [S]tate,’’
Hooper, 76 FR 71371 (quoting Anne
Lazar Thorn, 62 FR 12847, 12848
(1997)), the Agency has also long held
that revocation is warranted even where
a practitioner is still challenging the
underlying action. Bourne Pharmacy, 72
FR 18273, 18274 (2007); Wingfield
Drugs, 52 FR 27070, 27071 (1987). Thus,
it is of no consequence that the final
outcome of the underlying action may
still be pending. What is consequential
is my finding that Respondent is not
currently authorized to dispense
controlled substances in Ohio, the state
in which he is registered with the DEA.
Under Ohio law, ‘‘[n]o person shall
knowingly obtain, possess, or use a
controlled substance or a controlled
substance analog,’’ except 6 pursuant to
a ‘‘prescription issued by a licensed
health professional authorized to
prescribe drugs if the prescription was
issued for a legitimate medical
purpose.’’ Ohio Rev. Code Ann.
§ 2925.11(A), (B)(1)(d) (West 2021).
Ohio law further states that a
‘‘‘[l]icensed health professional
authorized to prescribe drugs’ or
‘prescriber’ means an individual who is
authorized by law to prescribe drugs or
dangerous drugs . . . in the course of
the individual’s professional practice.’’
Id. at § 4729.01(I). The definition further
provides a limited list of authorized
prescribers, the relevant provision of
which is ‘‘[a] physician authorized
under Chapter 4731 of the Revised Code
to practice medicine and surgery,
osteopathic medicine and surgery, or
podiatric medicine and surgery.’’ Id. at
§ 4729.01(I)(5). In addition, the Ohio
Uniform Controlled Substances Act
permits ‘‘[a] licensed health professional
authorized to prescribe drugs, if acting
in the course of professional practice, in
accordance with the laws regulating the
professional’s practice’’ to prescribe or
administer schedule II, III, IV, and V
controlled substances to patients. Id. at
§ 3719.06(A)(1)(a)–(b).
Here, the undisputed evidence in the
record is that Respondent currently
lacks authority to practice medicine in
Ohio. As already discussed, a physician
is authorized by law to prescribe or
administer drugs in Ohio only when
authorized to practice medicine and
6 Other
PO 00000
irrelevant exceptions omitted.
Frm 00112
Fmt 4703
Sfmt 4703
4943
surgery under Ohio law. Thus, because
Respondent lacks authority to practice
medicine in Ohio and, therefore, is not
authorized to handle controlled
substances in Ohio, Respondent is not
eligible to maintain a DEA registration.
Accordingly, I will order that
Respondent’s DEA registration be
revoked.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. FK6714504 issued to
Austin J. Kosier, M.D. Further, pursuant
to 28 CFR 0.100(b) and the authority
vested in me by 21 U.S.C. 823(f), I
hereby deny any pending application of
Austin J. Kosier, M.D. to renew or
modify this registration, as well as any
other pending application of Austin J.
Kosier, M.D., for additional registration
in Ohio. This Order is effective March
2, 2022.
Anne Milgram,
Administrator.
[FR Doc. 2022–01834 Filed 1–28–22; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–946]
Importer of Controlled Substances
Application: Mylan Pharmaceuticals
Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Mylan Pharmaceuticals Inc.
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to Supplementary
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 2, 2022. Such persons
may also file a written request for a
hearing on the application on or before
March 2, 2022.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
SUMMARY:
E:\FR\FM\31JAN1.SGM
31JAN1
Agencies
[Federal Register Volume 87, Number 20 (Monday, January 31, 2022)]
[Notices]
[Pages 4941-4943]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01834]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 22-4]
Austin J. Kosier, M.D.; Decision and Order
On September 30, 2021, the Acting Assistant Administrator,
Diversion Control Division, Drug Enforcement Administration
(hereinafter, DEA or Government), issued an Order to Show Cause
(hereinafter, OSC) to Austin J. Kosier, M.D. (hereinafter, Respondent)
of Zanesville, Ohio. OSC, at 1 and 3. The OSC proposed the revocation
of Respondent's Certificate of Registration No. FK6714504. It alleged
that Respondent ``[does] not have authority to dispense or prescribe
controlled substances in the [s]tate of Ohio, the state in which
[Respondent is] registered with DEA.'' Id. at 1 (citing 21 U.S.C.
824(a)(3)).
Specifically, the OSC alleged that on or about May 12, 2021, the
State Medical Board of Ohio issued an Order suspending Respondent's
state license to practice medicine and surgery. Id. at 2. The Order was
effective immediately and ordered that Respondent ``immediately cease
the practice of medicine and surgery in Ohio.'' Id.
The OSC notified Respondent of the right to request a hearing on
the allegations or to submit a written statement, while waiving the
right to a hearing, the procedures for electing each option, and the
consequences for failing to elect either option. Id. at 2 (citing 21
CFR 1301.43). The OSC also notified Respondent of the opportunity to
submit a corrective action plan. Id. at 3 (citing 21 U.S.C.
824(c)(2)(C)).
[[Page 4942]]
On October 25, 2021, Respondent timely requested a hearing by
email.\1\ Administrative Law Judge Exhibit (hereinafter, ALJX) 4
(Request for Hearing). Respondent's Request for Hearing also indicated
that Respondent was ``considering the submission of a corrective action
plan.'' Id.
---------------------------------------------------------------------------
\1\ Though the Request for Hearing itself is undated, the record
indicates that the Request for Hearing was filed on October 25,
2021. See Order Directing the Government to File Evidence Regarding
its Lack of State Authority Allegation and Briefing Schedule
(hereinafter, Briefing Schedule), at 1. I find that the Government's
service of the OSC was adequate and that the Request for Hearing was
timely filed on October 25, 2021.
---------------------------------------------------------------------------
The Office of Administrative Law Judges put the matter on the
docket and assigned it to Administrative Law Judge Teresa A. Wallbaum
(hereinafter, the ALJ). On October 25, 2021, the ALJ issued a Briefing
Schedule. See ALJX 5. The Government timely complied with the Briefing
Schedule by filing a Notice of Filing of Evidence and Motion for
Summary Disposition (hereinafter, Motion for Summary Disposition) on
November 10, 2021. Order Granting the Government's Motion for Summary
Disposition, and Recommended Rulings, Findings of Fact, Conclusions of
Law, and Decision of the Administrative Law Judge (hereinafter,
Recommended Decision or RD), at 2; see also ALJX 6. In its Motion for
Summary Disposition, the Government requested summary disposition and
recommended that Respondent's DEA registration be revoked based on
Respondent's lack of authority to handle controlled substances in Ohio,
the state in which he is registered with the DEA. Motion for Summary
Disposition, at 5. On November 30, 2021, Respondent untimely filed a
Memorandum in Opposition of Respondent [sic] to Government's Motion for
Summary Disposition (hereinafter, Respondent's Opposition). RD, at 2;
see also ALJX 7.\2\ Respondent's Opposition argued that there ``does
not exist and [sic] mandate under the [Controlled Substances Act]
whereas [the] tribunal shall or must revoke or suspend the [DEA
registration] of a physician under a state summary suspension.''
Respondent's Opposition, at 1. Respondent's Opposition also noted that
Respondent's state medical license, though suspended, was still intact;
\3\ that ``[t]he issue that led to his current case [was] unrelated to
the practice of medicine and was in no way arose [sic] in the course
and scope of practice''; \4\ and that ``[Respondent] has had no
previous issues in any way with his medical license in the past.'' Id.
Moreover, Respondent's Opposition highlighted ``the unbelievable work
[Respondent] has done and is continuing to do within the medical
community and specifically an online training and tutorial platform for
health care practitioners and medical students around the world.'' Id.
at 2-3. Finally, Respondent's Opposition highlighted that Respondent
``has also taken [the] opportunity to maintain and enhance his own
medical education'' with CME courses. Id. at 3. Respondent's Opposition
sought the denial of the Government's Motion for Summary Disposition
and for the Tribunal to either grant Respondent's request for a hearing
or to stay the matter pending the outcome of the Ohio Medical Board
hearing. Id.
---------------------------------------------------------------------------
\2\ As a result of Respondent's untimely filing, on November 30,
2021, the ALJ issued an Order to Show Good Cause Regarding
Respondent's Late Filing (hereinafter, Order to Show Good Cause).
See ALJX 8. On November 30, 2021, Respondent timely filed a Response
to Order to Show Good Cause stating that the untimely filing was due
to a death in Respondent's counsel's family. RD, at 2; see also ALJX
9. The ALJ found that ``the delay was minimal and caused no
prejudice to the Government'' and thus accepted Respondent's
Opposition. RD, at 2.
\3\ According to Respondent's Opposition, the Ohio Medical Board
``issued a summary suspension pending the outcome of a Medical Board
Hearing in January of 2022.'' Id. at 2. Further, according to
Respondent's Opposition, the suspension ``was based on a provision
in the Ohio Administrative Code that allows the Ohio Medical Board
to summarily suspend a license of a physician based on [the]
physician's entry into an intervention program to address a mental
health matter'' and ``[t]he matter at hand with [Respondent] is his
ongoing struggle with his homosexuality.'' Id.
\4\ See supra n.3.
---------------------------------------------------------------------------
On December 2, 2021, the ALJ granted the Government's Motion for
Summary Disposition, finding that ``[t]here is no genuine issue of
material fact in this case'' because ``[t]he Government has established
that Respondent currently lacks a medical license.'' RD, at 7-8. The
ALJ recommended that Respondent's DEA registration be revoked and that
any application to renew or modify his DEA registration be denied
``because Respondent lacks state authority to handle controlled
substances in Ohio.'' Id. at 8. By letter dated December 27, 2021, the
ALJ certified and transmitted the record to me for final Agency action.
Transmittal Letter, at 1. The ALJ also advised that neither party filed
exceptions. Id.
I issue this Decision and Order based on the entire record before
me. 21 CFR 1301.43(e). I make the following findings of fact.
Findings of Fact
Respondent's DEA Registration
According to Agency records, Respondent is the holder of DEA
Certificate of Registration No. FK6714504 at the registered address of
2916 Vangader Dr., Zanesville, OH 43701. Pursuant to this registration,
Respondent is authorized to dispense controlled substances in Schedules
II through V as a practitioner. Respondent's registration expires on
December 31, 2022.
The Status of Respondent's State License
On May 12, 2021, the State Medical Board of Ohio (hereinafter, the
Board) issued a Notice of Summary Suspension and Opportunity for
Hearing (hereinafter, Summary Suspension) and an Entry of Order.
Government Exhibit (hereinafter, GX) A, at 3 and 5. According to the
Summary Suspension, on or about December 16, 2019, ``the Franklin
County Court of Common Pleas filed an indictment alleging [Respondent]
had committed attempted unlawful sexual contact with a minor'' on or
about September 10, 2019. Id. Further, according to the Summary
Suspension, ``[o]n or about November 13, 2020, [Respondent] appeared
before the Court for a hearing on [his] application for intervention in
lieu of conviction for these offenses'' and ``[t]he Court granted
[Respondent's] application.'' Id. The Summary Suspension states that
``[Respondent] pleaded guilty to [the] felony offenses at a subsequent
hearing held on or about December 9, 2020'' and ``[t]he Court ordered
further proceedings be stayed while [Respondent was] under community
control.'' Id. In its Entry of Order on May 12, 2021, the Board found
that ``[Respondent's] continued practice presents a danger of immediate
and serious harm to the public'' and ordered, effective immediately,
that Respondent's license to practice medicine and surgery in the state
of Ohio be summarily suspended, that Respondent ``immediately cease the
practice of medicine and surgery in Ohio,'' and that Respondent
``immediately refer all active patients to other appropriate
physicians.'' Id. at 3.
According to Ohio's online records, of which I take official
notice, Respondent's medical license is still suspended and
inactive.\5\ Ohio License
[[Page 4943]]
Look Up, https://elicense.ohio.gov/oh_verifylicense (last visited date
of signature of this Order). Accordingly, I find that Respondent is not
currently licensed to practice medicine in Ohio, the state in which he
is registered with the DEA.
---------------------------------------------------------------------------
\5\ Under the Administrative Procedure Act, an agency ``may take
official notice of facts at any stage in a proceeding--even in the
final decision.'' United States Department of Justice, Attorney
General's Manual on the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). Pursuant to 5 U.S.C. 556(e),
``[w]hen an agency decision rests on official notice of a material
fact not appearing in the evidence in the record, a party is
entitled, on timely request, to an opportunity to show the
contrary.'' Accordingly, Respondent may dispute my finding by filing
a properly supported motion for reconsideration of findings of fact
within fifteen calendar days of the date of this Order. Any such
motion and response shall be filed and served by email to the other
party and to Office of the Administrator, Drug Enforcement
Administration at [email protected].
---------------------------------------------------------------------------
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized
to suspend or revoke a registration issued under section 823 of the
Controlled Substances Act (hereinafter, CSA) ``upon a finding that the
registrant . . . has had his State license or registration suspended .
. . [or] revoked . . . by competent State authority and is no longer
authorized by State law to engage in the . . . dispensing of controlled
substances.'' With respect to a practitioner, the DEA has also long
held that the possession of authority to dispense controlled substances
under the laws of the state in which a practitioner engages in
professional practice is a fundamental condition for obtaining and
maintaining a practitioner's registration. See, e.g., James L. Hooper,
M.D., 76 FR 71,371 (2011), pet. for rev. denied, 481 F. App'x 826 (4th
Cir. 2012); Frederick Marsh Blanton, M.D., 43 FR 27616, 27617 (1978).
This rule derives from the text of two provisions of the CSA.
First, Congress defined the term ``practitioner'' to mean ``a physician
. . . or other person licensed, registered, or otherwise permitted, by
. . . the jurisdiction in which he practices . . . , to distribute,
dispense, . . . [or] administer . . . a controlled substance in the
course of professional practice.'' 21 U.S.C. 802(21). Second, in
setting the requirements for obtaining a practitioner's registration,
Congress directed that ``[t]he Attorney General shall register
practitioners . . . if the applicant is authorized to dispense . . .
controlled substances under the laws of the State in which he
practices.'' 21 U.S.C. 823(f). Because Congress has clearly mandated
that a practitioner possess state authority in order to be deemed a
practitioner under the CSA, the DEA has held repeatedly that revocation
of a practitioner's registration is the appropriate sanction whenever
he is no longer authorized to dispense controlled substances under the
laws of the state in which he practices. See, e.g., James L. Hooper, 76
FR 71371-72; Sheran Arden Yeates, M.D., 71 FR 39130, 39131 (2006);
Dominick A. Ricci, M.D., 58 FR 51104, 51105 (1993); Bobby Watts, M.D.,
53 FR 11919, 11920 (1988); Frederick Marsh Blanton, 43 FR 27617.
Moreover, because ``the controlling question'' in a proceeding
brought under 21 U.S.C. 824(a)(3) is whether the holder of a
practitioner's registration ``is currently authorized to handle
controlled substances in the [S]tate,'' Hooper, 76 FR 71371 (quoting
Anne Lazar Thorn, 62 FR 12847, 12848 (1997)), the Agency has also long
held that revocation is warranted even where a practitioner is still
challenging the underlying action. Bourne Pharmacy, 72 FR 18273, 18274
(2007); Wingfield Drugs, 52 FR 27070, 27071 (1987). Thus, it is of no
consequence that the final outcome of the underlying action may still
be pending. What is consequential is my finding that Respondent is not
currently authorized to dispense controlled substances in Ohio, the
state in which he is registered with the DEA.
Under Ohio law, ``[n]o person shall knowingly obtain, possess, or
use a controlled substance or a controlled substance analog,'' except
\6\ pursuant to a ``prescription issued by a licensed health
professional authorized to prescribe drugs if the prescription was
issued for a legitimate medical purpose.'' Ohio Rev. Code Ann. Sec.
2925.11(A), (B)(1)(d) (West 2021). Ohio law further states that a
```[l]icensed health professional authorized to prescribe drugs' or
`prescriber' means an individual who is authorized by law to prescribe
drugs or dangerous drugs . . . in the course of the individual's
professional practice.'' Id. at Sec. 4729.01(I). The definition
further provides a limited list of authorized prescribers, the relevant
provision of which is ``[a] physician authorized under Chapter 4731 of
the Revised Code to practice medicine and surgery, osteopathic medicine
and surgery, or podiatric medicine and surgery.'' Id. at Sec.
4729.01(I)(5). In addition, the Ohio Uniform Controlled Substances Act
permits ``[a] licensed health professional authorized to prescribe
drugs, if acting in the course of professional practice, in accordance
with the laws regulating the professional's practice'' to prescribe or
administer schedule II, III, IV, and V controlled substances to
patients. Id. at Sec. 3719.06(A)(1)(a)-(b).
---------------------------------------------------------------------------
\6\ Other irrelevant exceptions omitted.
---------------------------------------------------------------------------
Here, the undisputed evidence in the record is that Respondent
currently lacks authority to practice medicine in Ohio. As already
discussed, a physician is authorized by law to prescribe or administer
drugs in Ohio only when authorized to practice medicine and surgery
under Ohio law. Thus, because Respondent lacks authority to practice
medicine in Ohio and, therefore, is not authorized to handle controlled
substances in Ohio, Respondent is not eligible to maintain a DEA
registration. Accordingly, I will order that Respondent's DEA
registration be revoked.
Order
Pursuant to 28 CFR 0.100(b) and the authority vested in me by 21
U.S.C. 824(a), I hereby revoke DEA Certificate of Registration No.
FK6714504 issued to Austin J. Kosier, M.D. Further, pursuant to 28 CFR
0.100(b) and the authority vested in me by 21 U.S.C. 823(f), I hereby
deny any pending application of Austin J. Kosier, M.D. to renew or
modify this registration, as well as any other pending application of
Austin J. Kosier, M.D., for additional registration in Ohio. This Order
is effective March 2, 2022.
Anne Milgram,
Administrator.
[FR Doc. 2022-01834 Filed 1-28-22; 8:45 am]
BILLING CODE 4410-09-P